Monoclonal antibody therapeutics have become the most rapidly growing category of biological drugs because of their high specificity, strong targeting, low side effects, and remarkable curative effect. In addition to the attractive therapeutic properties, the ability to quickly develop a robust production process to manufacture monoclonal antibodies has become a key factor for their commercial success. The apparent convenience and speed of monoclonal antibody production processes enable candidate products to quickly enter clinical trials. The scalability and robustness of these processes facilitate reliable commercial production at large-scale.

Bioworkshops team has been devoted to the field of monoclonal antibody process development for many years. The team members combined experience includes development of more than 40 biological drug products with 4 reaching commercial sale and more than 10 products in phase III clinical research covering new drug applications in China, the United States, Europe, and Australia.

Time: 17^th Nov. 2020, 19:30—21:00

Speaker: Dr. Alex Zhu

Abstract: As an important branch of chemical engineering, core aspects of cell culture technology can be neatly summarized as “three transfers and one reaction”. That is, momentum transfer, heat transfer, mass transfer and one reaction. This online interactive presentation mainly focuses on the technical challenges associated with mass and momentum transfer in the scale-up of biopharmaceutical upstream processes and current best-practice coping strategies supported with relevant case-studies.